<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829838</url>
  </required_header>
  <id_info>
    <org_study_id>700/RC/KEMU</org_study_id>
    <nct_id>NCT04829838</nct_id>
  </id_info>
  <brief_title>Comparison of Efficacy of Phenytoin With Levetireacetam for the Management of Children With Status Epilepticus</brief_title>
  <official_title>Comparison of Efficacy of Phenytoin With Levetireacetam for the Management of Children With Status Epilepticus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ayesha tariq</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King Edward Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King Edward Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of studyis to compare the efficacy of phenytoin with levetiracetam for the&#xD;
      management of children with status epilepticus.Study performa consists of demographic&#xD;
      variables,exclusion criteria,history of epilepsy and efficacy achieved or not.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After getting informed consent 244 children with status epilepticus will be randomly&#xD;
      classified into two groups.one group will receive levetireacetam and other group will be&#xD;
      given phenytoin and their efficacy will be compared by observing them for breakthrough fits&#xD;
      for next 48 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2019</start_date>
  <completion_date type="Anticipated">July 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 26, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>comparison of efficacy of levetireacetam with phenytoin for the management of children with status epilepticus</measure>
    <time_frame>48 hours</time_frame>
    <description>the intervention will be considered efficacious if child will not have breakthrough fits for 48 hours</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">244</enrollment>
  <condition>Status Epilepticus</condition>
  <arm_group>
    <arm_group_label>Intravenous levetireacetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:Intravenous levetireacetam will be given at a loading dose of 20-30mg/kg then it will be added in maintainance dose of (5-30mg/kg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravenous phenytoin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous phenytoin will be given in loading dose of 20mg/kg then it will be added in maintainance dose i-e 5-8mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous levetireacetam</intervention_name>
    <description>phenytoin is considered as control drug in the study</description>
    <arm_group_label>Intravenous levetireacetam</arm_group_label>
    <arm_group_label>intravenous phenytoin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  childen of age less than 12 years either gender admitted in pediatric emergency with&#xD;
             status epilepticus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  children already taking either of trial drug or failed treatment with either of trial&#xD;
             drug.children with comorbid conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haroon Hamid, MBBS,FCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Edward Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ayesha tariq, MBBS</last_name>
    <phone>0923360495413</phone>
    <email>docayesha86@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>mohammad Haroon Hamid, MBBS,FCPS</last_name>
    <phone>0923008880916</phone>
    <email>PROFHAROON@KEMU.EDU.PK</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ayesha Tariq</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ayesha tariq, MBBS</last_name>
      <phone>0923360495413</phone>
      <email>docayesha86@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>Smith DM, McGinnis EL, Walleigh DJ, Abend NS. Management of Status Epilepticus in Children. J Clin Med. 2016 Apr 13;5(4). pii: E47. doi: 10.3390/jcm5040047. Review.</citation>
    <PMID>27089373</PMID>
  </reference>
  <reference>
    <citation>Abend NS, Loddenkemper T. Pediatric status epilepticus management. Curr Opin Pediatr. 2014 Dec;26(6):668-74. doi: 10.1097/MOP.0000000000000154. Review.</citation>
    <PMID>25304961</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>King Edward Medical University</investigator_affiliation>
    <investigator_full_name>ayesha tariq</investigator_full_name>
    <investigator_title>Post graduate resident in Pediatrics medicine(MD Paeds)</investigator_title>
  </responsible_party>
  <keyword>status epilepticus, children, phenytoin, levetireacetam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

